Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 41

Sort by

Sort Order Select

Journal Articles

Biomarker correlates of clinical outcomes from a global Phase 1b study of JNJ-90014496, CD20/CD19 bi-specific chimeric antigen receptor (CAR) T-cell therapy for patients with large B-cell lymphoma (LBCL)

Blood (2025) 146 (Supplement 1): 568.

https://doi.org/10.1182/blood-2025-568

Published: 2025

Journal Articles

Fixed treatment duration mosunetuzumab continues to demonstrate clinically meaningful outcomes in patients with relapsed/refractory (R/R) follicular lymphoma (FL) after ≥2 prior therapies: 5-year follow-up of a pivotal Phase II study

Blood (2025) 146 (Supplement 1): 5352.

https://doi.org/10.1182/blood-2025-5352

Published: 2025

Journal Articles

Mosunetuzumab in combination with zanubrutinib is safe in patients with relapsed/refractory follicular lymphoma: Safety run-in results from the FIL-mozart Phase II study

Rita Tavarozzi, Marco Ladetto, Francesca Bonello, Umberto Vitolo, Pier Luigi Zinzani, Angela Ferrari, Beatrice Casadei, Matthew Ku, Luigi Marcheselli, Stefano Luminari

Blood (2025) 146 (Supplement 1): 7096.

https://doi.org/10.1182/blood-2025-7096

Published: 2025

Journal Articles

Sustained clinical benefit of glofitamab plus gemcitabine and oxaliplatin (GemOx) versus rituximab plus GemOx (R-GemOx) in patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL): 3-year follow-up of STARGLO

Blood (2025) 146 (Supplement 1): 5519.

https://doi.org/10.1182/blood-2025-5519

Published: 2025

Journal Articles

Glofitamab plus gemcitabine and oxaliplatin (GemOx) vs rituximab (R)-GemOx in patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL): Efficacy and safety in patient subgroups

Haifaa Abdulhaq, William Townsend, Matthew Ku, Gareth P. Gregory, Jeremy Abramson, Huiqiang Huang, Huilai Zhang, Dok Hyun Yoon, Won-Seog Kim, Herve Ghesquieres, Mark Hertzberg, Qing-Yuan Zhang, Murali Kesavan, Estefania Mulvihill, Martine Joanna Kallemeijn, Richard Ta, Voleak Choeurng, Linda Lundberg, Christopher Fox

Blood (2025) 146 (Supplement 1): 3743.

https://doi.org/10.1182/blood-2025-3743

Published: 2025

Journal Articles

Long-term 3-year follow-up of mosunetuzumab in relapsed or refractory follicular lymphoma after ≥2 prior therapies

Blood (2025) 145 (7): 708–719.

https://doi.org/10.1182/blood.2024025454

Published: 2025

Includes: Supplemental data

Journal Articles

Mosunetuzumab and Zanubrutinib in Relapsed/Refractory Follicular Lymphoma Patients (MOZART): A Phase II, Chemo-Free Trial from Fondazione Italiana Linfomi (FIL)

Marco Ladetto, Rita Tavarozzi, Matthew Ku, Luca Arcaini, Carola Boccomini, Beatrice Casadei, Annalisa Chiarenza, Annarita Conconi, Ilaria Del Giudice, Michele Merli, Maria Elena Nizzoli, Stefano Luminari

Blood (2024) 144 (Supplement 1): 3042.1.

https://doi.org/10.1182/blood-2024-201305

Published: 2024

Journal Articles

Primary Results of Patient-Reported Outcomes in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma Treated with Glofitamab Plus Gemcitabine and Oxaliplatin (Glofit-GemOx) Versus Rituximab Plus GemOx (R-GemOx) from the Phase III Starglo Study

Gareth P. Gregory, Jeremy S. Abramson, Hui-Qiang Huang, Qing-Yuan Zhang, Matthew Ku, Dok Hyun Yoon, Christopher P. Fox, Haifaa Abdulhaq, William Townsend, Joan Ashby, Alana Harris, Victor Orellana-Noia, Stephen Simko, Martine Kallemeijn, Richard Ta, James Relf, Huang Huang, Linda Lundberg, Huilai Zhang

Blood (2024) 144 (Supplement 1): 5132.

https://doi.org/10.1182/blood-2024-198424

Published: 2024

Journal Articles

Evaluation of Anti-Tumor Activity and Impact on T Cell Activation of Glofitamab in Combination with Gemcitabine and Oxaliplatin (Glofit-GemOx)

Marina Bacac, Johannes Sam, Won Seog Kim, Gareth P. Gregory, Matthew Ku, Sylvia Herter, Christian Klein, Pablo Umana, Stephen Simko, Victor Orellana-Noia, Linda Lundberg, Alessia Bottos

Blood (2024) 144 (Supplement 1): 2990.

https://doi.org/10.1182/blood-2024-200753

Published: 2024

Journal Articles

Deep and Sustained Responses in Patients with CLL Treated with Zanubrutinib or Zanubrutinib + Obinutuzumab in Phase 1/2 AU-003 and Phase 1b GA-101 Studies: A Report from the Zanubrutinib Extension Study

Constantine S. Tam, Stephen S. Opat, Eileen Grace Merriman, Jan A. Burger, Emma Verner, Paula Marlton, David Gottlieb, Ian W. Flinn, Sumit Madan, Matthew Ku, Radha Prathikanti, Heather Allewelt, Tian Tian, Remus Vezan, Gavin Cull

Blood (2024) 144 (Supplement 1): 3255.

https://doi.org/10.1182/blood-2024-200363

Published: 2024

Journal Articles

Mosunetuzumab Continues to Demonstrate Clinically Meaningful Outcomes in Patients with Relapsed and/or Refractory Follicular Lymphoma after ≥2 Prior Therapies Including Those with a History of POD24: 4-Year Follow-up of a Pivotal Phase II Study

Blood (2024) 144 (Supplement 1): 4407.

https://doi.org/10.1182/blood-2024-197897

Published: 2024

Journal Articles

A Randomized Phase 2, Investigator-Led Trial of Glofitamab-R-CHOP or Glofitamab-Polatuzumab Vedotin-R-CHP (COALITION) in Younger Patients with High Burden, High-Risk Large B-Cell Lymphoma Demonstrates Safety, Uncompromised Chemotherapy Intensity, a High Rate of Durable Remissions, and Unique FDG-PET Response Characteristics

Blood (2024) 144 (Supplement 1): 582.

https://doi.org/10.1182/blood-2024-204930

Published: 2024

Journal Articles

The influence of immunodeficiency, disease features, and patient characteristics on survival in plasmablastic lymphoma

Blood (2024) 143 (2): 152–165.

https://doi.org/10.1182/blood.2023021348

Published: 2024

Includes: Supplemental data

Journal Articles

A Window Study of Acalabrutinib & Rituximab, Followed By Chemotherapy & Autograft (ASCT) in Fit Patients with Treatment Naïve Mantle Cell Lymphoma (MCL): First Report of the Investigator-Initiated Australasian Leukaemia & Lymphoma Group NHL33 ‘Wamm’ Trial

Blood (2023) 142 (Supplement 1): 735.

https://doi.org/10.1182/blood-2023-178403

Published: 2023

Journal Articles

Mosunetuzumab Monotherapy Continues to Demonstrate Durable Responses in Patients with Relapsed and/or Refractory Follicular Lymphoma after ≥2 Prior Therapies: 3-Year Follow-up from a Pivotal Phase II Study

Blood (2023) 142 (Supplement 1): 603.

https://doi.org/10.1182/blood-2023-173692

Published: 2023

Journal Articles

Mosunetuzumab Monotherapy Demonstrates Activity and a Manageable Safety Profile in Patients with Relapsed or Refractory Richter's Transformation

Chan Y. Cheah, Sarit Assouline, Ross Baker, Nancy L. Bartlett, Dima El-Sharkawi, Pratyush Giri, Matthew Ku, Stephen J. Schuster, Matthew Matasar, John Radford, Michael C. Wei, Shen Yin, Iris To, Jiangeng Huang, Antonia Kwan, L. Elizabeth Budde

Blood (2023) 142 (Supplement 1): 614.

https://doi.org/10.1182/blood-2023-173796

Published: 2023

Journal Articles

Mosunetuzumab Monotherapy Demonstrates Durable Efficacy with a Manageable Safety Profile in Patients with Relapsed/Refractory Follicular Lymphoma Who Received ≥2 Prior Therapies: Updated Results from a Pivotal Phase II Study

Nancy L. Bartlett, Laurie H. Sehn, Matthew J. Matasar, Stephen J. Schuster, Sarit Assouline, Pratyush Giri, John Kuruvilla, Miguel Canales, Sascha Dietrich, Keith Fay, Matthew Ku, Loretta J. Nastoupil, Michael C. Wei, Shen Yin, Iris To, Huang Huang, Juliana Min, Elicia Penuel, L. Elizabeth Budde

Blood (2022) 140 (Supplement 1): 1467–1470.

https://doi.org/10.1182/blood-2022-157691

Published: 2022

Journal Articles

Predictors of Adverse Clinical Outcome in Diffuse Large B-Cell Lymphoma Richter Transformation of CLL/SLL: A Consortium of Richter Transformation Investigators (CORTI) Multicenter Study across 8 US, UK, and Australian Academic Centers

Blood (2022) 140 (Supplement 1): 2053–2055.

https://doi.org/10.1182/blood-2022-155950

Published: 2022

Journal Articles

Magrolimab in Combination with Rituximab + Chemotherapy in Patients with Relapsed or Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)

Joseph Maakaron, Adam S. Asch, Leslie L. Popplewell, Graham P. Collins, Ian W. Flinn, Nilanjan Ghosh, Colin Keane, Matthew Ku, Amitkumar Mehta, Mark Roschewski, Carol O'Hear, Xuehan Ren, Bertha Villa, Indu Lal, Sonali M. Smith, Ranjana H. Advani

Blood (2022) 140 (Supplement 1): 3728–3730.

https://doi.org/10.1182/blood-2022-167772

Published: 2022

Journal Articles

Characteristics and Outcomes of Elderly Patients with Classical Hodgkin Lymphoma (cHL): An Australian Lymphoma Alliance (ALA), and Lymphoma and Related Disease Registry (LaRDR) Study

Zhong Goh, Maya Latimer, Katharine L. Lewis, Chan Yoon Cheah, Pietro Di Ciaccio, Tania Cushion, Eliza Hawkes, Sean Harrop, Matthew Ku, Ashlea Campbell, Nada Hamad, Erica M. Wood, Eliza Chung, Pin-Yen Chen, Tara Cochrane

Blood (2022) 140 (Supplement 1): 9413–9415.

https://doi.org/10.1182/blood-2022-156782

Published: 2022

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Biomarker correlates of clinical outcomes from a global Phase 1b study of JNJ-90014496, CD20/CD19 bi-specific chimeric antigen receptor (CAR) T-cell therapy for patients with large B-cell lymphoma (LBCL)

Fixed treatment duration mosunetuzumab continues to demonstrate clinically meaningful outcomes in patients with relapsed/refractory (R/R) follicular lymphoma (FL) after ≥2 prior therapies: 5-year follow-up of a pivotal Phase II study

Mosunetuzumab in combination with zanubrutinib is safe in patients with relapsed/refractory follicular lymphoma: Safety run-in results from the FIL-mozart Phase II study

Sustained clinical benefit of glofitamab plus gemcitabine and oxaliplatin (GemOx) versus rituximab plus GemOx (R-GemOx) in patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL): 3-year follow-up of STARGLO

Glofitamab plus gemcitabine and oxaliplatin (GemOx) vs rituximab (R)-GemOx in patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL): Efficacy and safety in patient subgroups

Long-term 3-year follow-up of mosunetuzumab in relapsed or refractory follicular lymphoma after ≥2 prior therapies

Mosunetuzumab and Zanubrutinib in Relapsed/Refractory Follicular Lymphoma Patients (MOZART): A Phase II, Chemo-Free Trial from Fondazione Italiana Linfomi (FIL)

Primary Results of Patient-Reported Outcomes in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma Treated with Glofitamab Plus Gemcitabine and Oxaliplatin (Glofit-GemOx) Versus Rituximab Plus GemOx (R-GemOx) from the Phase III Starglo Study

Evaluation of Anti-Tumor Activity and Impact on T Cell Activation of Glofitamab in Combination with Gemcitabine and Oxaliplatin (Glofit-GemOx)

Deep and Sustained Responses in Patients with CLL Treated with Zanubrutinib or Zanubrutinib + Obinutuzumab in Phase 1/2 AU-003 and Phase 1b GA-101 Studies: A Report from the Zanubrutinib Extension Study

Mosunetuzumab Continues to Demonstrate Clinically Meaningful Outcomes in Patients with Relapsed and/or Refractory Follicular Lymphoma after ≥2 Prior Therapies Including Those with a History of POD24: 4-Year Follow-up of a Pivotal Phase II Study

The influence of immunodeficiency, disease features, and patient characteristics on survival in plasmablastic lymphoma

A Window Study of Acalabrutinib & Rituximab, Followed By Chemotherapy & Autograft (ASCT) in Fit Patients with Treatment Naïve Mantle Cell Lymphoma (MCL): First Report of the Investigator-Initiated Australasian Leukaemia & Lymphoma Group NHL33 ‘Wamm’ Trial

Mosunetuzumab Monotherapy Continues to Demonstrate Durable Responses in Patients with Relapsed and/or Refractory Follicular Lymphoma after ≥2 Prior Therapies: 3-Year Follow-up from a Pivotal Phase II Study

Mosunetuzumab Monotherapy Demonstrates Activity and a Manageable Safety Profile in Patients with Relapsed or Refractory Richter's Transformation

Mosunetuzumab Monotherapy Demonstrates Durable Efficacy with a Manageable Safety Profile in Patients with Relapsed/Refractory Follicular Lymphoma Who Received ≥2 Prior Therapies: Updated Results from a Pivotal Phase II Study

Predictors of Adverse Clinical Outcome in Diffuse Large B-Cell Lymphoma Richter Transformation of CLL/SLL: A Consortium of Richter Transformation Investigators (CORTI) Multicenter Study across 8 US, UK, and Australian Academic Centers

Magrolimab in Combination with Rituximab + Chemotherapy in Patients with Relapsed or Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)

Characteristics and Outcomes of Elderly Patients with Classical Hodgkin Lymphoma (cHL): An Australian Lymphoma Alliance (ALA), and Lymphoma and Related Disease Registry (LaRDR) Study

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only